277 related articles for article (PubMed ID: 28096270)
1. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of
Fujii T; Barzi A; Sartore-Bianchi A; Cassingena A; Siravegna G; Karp DD; Piha-Paul SA; Subbiah V; Tsimberidou AM; Huang HJ; Veronese S; Di Nicolantonio F; Pingle S; Vibat CRT; Hancock S; Berz D; Melnikova VO; Erlander MG; Luthra R; Kopetz ES; Meric-Bernstam F; Siena S; Lenz HJ; Bardelli A; Janku F
Clin Cancer Res; 2017 Jul; 23(14):3657-3666. PubMed ID: 28096270
[No Abstract] [Full Text] [Related]
2. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
[No Abstract] [Full Text] [Related]
4. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.
Janku F; Zhang S; Waters J; Liu L; Huang HJ; Subbiah V; Hong DS; Karp DD; Fu S; Cai X; Ramzanali NM; Madwani K; Cabrilo G; Andrews DL; Zhao Y; Javle M; Kopetz ES; Luthra R; Kim HJ; Gnerre S; Satya RV; Chuang HY; Kruglyak KM; Toung J; Zhao C; Shen R; Heymach JV; Meric-Bernstam F; Mills GB; Fan JB; Salathia NS
Clin Cancer Res; 2017 Sep; 23(18):5648-5656. PubMed ID: 28536309
[No Abstract] [Full Text] [Related]
6. Detection of
Michaelidou K; Koutoulaki C; Mavridis K; Vorrias E; Papadaki MA; Koutsopoulos AV; Mavroudis D; Agelaki S
Cells; 2020 Nov; 9(11):. PubMed ID: 33233668
[No Abstract] [Full Text] [Related]
7. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
8. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
11. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
Nakano Y; Kitago M; Matsuda S; Nakamura Y; Fujita Y; Imai S; Shinoda M; Yagi H; Abe Y; Hibi T; Fujii-Nishimura Y; Takeuchi A; Endo Y; Itano O; Kitagawa Y
Br J Cancer; 2018 Mar; 118(5):662-669. PubMed ID: 29360815
[TBL] [Abstract][Full Text] [Related]
13. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Janku F; Angenendt P; Tsimberidou AM; Fu S; Naing A; Falchook GS; Hong DS; Holley VR; Cabrilo G; Wheler JJ; Piha-Paul SA; Zinner RG; Bedikian AY; Overman MJ; Kee BK; Kim KB; Kopetz ES; Luthra R; Diehl F; Meric-Bernstam F; Kurzrock R
Oncotarget; 2015 May; 6(14):12809-21. PubMed ID: 25980577
[TBL] [Abstract][Full Text] [Related]
14. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
[TBL] [Abstract][Full Text] [Related]
15. Serum-Based KRAS
Kim JS; Bae GE; Kim SH; Choi MK; Yeo MK
Front Oncol; 2020; 10():604772. PubMed ID: 33585224
[TBL] [Abstract][Full Text] [Related]
16. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
17. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
[TBL] [Abstract][Full Text] [Related]
18. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
19. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.
Hu Y; Ulrich BC; Supplee J; Kuang Y; Lizotte PH; Feeney NB; Guibert NM; Awad MM; Wong KK; Jänne PA; Paweletz CP; Oxnard GR
Clin Cancer Res; 2018 Sep; 24(18):4437-4443. PubMed ID: 29567812
[No Abstract] [Full Text] [Related]
20. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.
Mehrotra M; Singh RR; Chen W; Huang RSP; Almohammedsalim AA; Barkoh BA; Simien CM; Hernandez M; Behrens C; Patel KP; Routbort MJ; Broaddus RR; Medeiros LJ; Wistuba II; Kopetz S; Luthra R
J Mol Diagn; 2017 Jul; 19(4):514-524. PubMed ID: 28506684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]